Using a 23-plex bead-based immunoassay, we found that knockdown of LDHC significantly increased the levels of cancer cell-derived GM-CSF, IFN-γ, MCP-1, and CXCL1, while reducing IL-6 and Gal-9 levels (Fig. 3A). The gene discussed is CCL2; the disease is cancer.